# NRG-BN001 (NCT02179086)

> Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

No report yet. It can be ordered.

- Drugs tested: none (the trial tests a strategy, not a drug)
- Indication: newly diagnosed glioblastoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02179086
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: NRG Oncology
- Conditions: Glioblastoma
- Interventions: Photon Beam Radiation Therapy; Proton Beam Radiation Therapy; Temozolomide
- Enrollment: 624
- Primary outcome: Median Survival Time (Within Center Group)

## Indexed commentary on NRG-BN001 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 7 posts on X
- 2 YouTube videos
- 1 podcast episode

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nrg-bn001-nct02179086

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02179086", "email": "<work email>"}; the inbox owner confirms by the emailed link.